Cerebrovascular responsiveness to NG-nitro-L-arginine methyl ester in spontaneously diabetic rats. 1996

I P Fouyas, and P A Kelly, and I M Ritchie, and I R Whittle
Department of Clinical Neurosciences, University of Edinburgh.

1. There is evidence that endothelial dysfunction is associated with diabetes mellitus. The purpose of the present study was to assess local cerebral blood flow (LCBF) and cerebrovascular responsiveness to the NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME) in spontaneously diabetic insulin-dependent BioBred (BB) rats. 2. Diabetic rats, and non-diabetic controls, were treated with L-NAME (30 mg kg-1, i.v.) or saline, 20 min prior to the measurement of LCBF by the fully quantitative [14C]-iodoantipyrine autoradiographic technique. 3. There were no significant differences in physiological parameters (blood pH, PCO2, and PO2, rectal temperature, arterial blood pressure, or plasma glucose) between any of the groups of rats, and no difference in either the extent or the temporal characteristics of the hypertensive response to L-NAME between diabetic and non-diabetic rats. 4. In diabetic rats, a global reduction in basal LCBF was observed, although significant reductions (between -20 and -30%) were found in only 5 (mainly subcortical) out of the 13 brain regions measured. Following L-NAME injection, significant reductions in LCBF (between -20 and -40%) were found in the non-diabetic animals. In diabetic animals treated with L-NAME, a significant reduction in LCBF was measured only in the hypothalamus (-33%). 5. The cerebrovascular response to acute L-NAME is attenuated in spontaneously diabetic insulin-dependent BB rats. This would be consistent with the endothelial dysfunction in cerebral vessels, known to be associated with diabetes mellitus and it is possible that a loss of NO-induced dilator tone, amongst other factors, may underlie the observed reductions of basal LCBF in these animals.

UI MeSH Term Description Entries
D008297 Male Males
D011913 Rats, Inbred BB A strain of Rattus norvegicus which is a model for spontaneous insulin-dependent diabetes mellitus (DIABETES MELLITUS, INSULIN-DEPENDENT). BB Wistar Rats,Bio-Breeding Inbred Rats,Rats, BB,BB Rat,BB Rat, Inbred,BB Rats,BB Rats, Inbred,Bio Breeding Inbred Rats,Bio-Breeding Inbred Rat,Inbred BB Rat,Inbred BB Rats,Inbred Rat, Bio-Breeding,Inbred Rats, Bio-Breeding,Rat, BB,Rat, Bio-Breeding Inbred,Rat, Inbred BB,Rats, BB Wistar,Rats, Bio-Breeding Inbred,Wistar Rats, BB
D002560 Cerebrovascular Circulation The circulation of blood through the BLOOD VESSELS of the BRAIN. Brain Blood Flow,Regional Cerebral Blood Flow,Cerebral Blood Flow,Cerebral Circulation,Cerebral Perfusion Pressure,Circulation, Cerebrovascular,Blood Flow, Brain,Blood Flow, Cerebral,Brain Blood Flows,Cerebral Blood Flows,Cerebral Circulations,Cerebral Perfusion Pressures,Circulation, Cerebral,Flow, Brain Blood,Flow, Cerebral Blood,Perfusion Pressure, Cerebral,Pressure, Cerebral Perfusion
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001120 Arginine An essential amino acid that is physiologically active in the L-form. Arginine Hydrochloride,Arginine, L-Isomer,DL-Arginine Acetate, Monohydrate,L-Arginine,Arginine, L Isomer,DL Arginine Acetate, Monohydrate,Hydrochloride, Arginine,L Arginine,L-Isomer Arginine,Monohydrate DL-Arginine Acetate
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D019001 Nitric Oxide Synthase An NADPH-dependent enzyme that catalyzes the conversion of L-ARGININE and OXYGEN to produce CITRULLINE and NITRIC OXIDE. NO Synthase,Nitric-Oxide Synthase,Nitric-Oxide Synthetase,Nitric Oxide Synthetase,Oxide Synthase, Nitric,Synthase, Nitric Oxide
D019331 NG-Nitroarginine Methyl Ester A non-selective inhibitor of nitric oxide synthase. It has been used experimentally to induce hypertension. L-NAME,N omega-Nitro-L-arginine Methyl Ester,NG-Nitro-L-Arginine Methyl Ester,N(G)-Nitro-L-arginine Methyl Ester,N(G)-Nitroarginine Methyl Ester,N(omega)-Nitro-L-arginine Methyl Ester,NG-Nitroarginine Methyl Ester, D-Orn-Isomer,NG-Nitroarginine Methyl Ester, L-Orn-Isomer, Monohydrochloride,Methyl Ester, NG-Nitro-L-Arginine,Methyl Ester, NG-Nitroarginine,N omega Nitro L arginine Methyl Ester,NG Nitro L Arginine Methyl Ester,NG Nitroarginine Methyl Ester,NG Nitroarginine Methyl Ester, D Orn Isomer

Related Publications

I P Fouyas, and P A Kelly, and I M Ritchie, and I R Whittle
November 1995, British journal of pharmacology,
I P Fouyas, and P A Kelly, and I M Ritchie, and I R Whittle
June 2000, Lancet (London, England),
I P Fouyas, and P A Kelly, and I M Ritchie, and I R Whittle
March 1994, Neuroscience,
I P Fouyas, and P A Kelly, and I M Ritchie, and I R Whittle
March 1994, Brain research,
I P Fouyas, and P A Kelly, and I M Ritchie, and I R Whittle
January 1997, Fundamental & clinical pharmacology,
I P Fouyas, and P A Kelly, and I M Ritchie, and I R Whittle
October 1994, Journal of chromatography. B, Biomedical applications,
I P Fouyas, and P A Kelly, and I M Ritchie, and I R Whittle
April 1995, British journal of pharmacology,
I P Fouyas, and P A Kelly, and I M Ritchie, and I R Whittle
October 1992, British journal of pharmacology,
I P Fouyas, and P A Kelly, and I M Ritchie, and I R Whittle
July 1996, Journal of cardiovascular pharmacology,
I P Fouyas, and P A Kelly, and I M Ritchie, and I R Whittle
December 1991, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
Copied contents to your clipboard!